Presented by Jessica Palmer at the Society for Birth Defects and Research Meeting; June, 2022
There have been increased efforts in the pharmaceutical and chemical industries to incorporate new approach methods (NAMs) in vitro,, ex vivo, or in silico) earlier in the product development pipeline prior to in vivo testing.
Presented by Jessica Palmer at the Society for Toxicology Meeting; March, 2022
There have been increased efforts in the pharmaceutical and chemical industries to incorporate new approach methods (NAMs) (in vitro, ex vivo, or in silico) earlier in the product development pipeline prior to in vivo testing.
Presented by Jessica Palmer at the 11th World Congress on Alternatives and Animal Use in the Life Sciences; August, 2021
Implementing screening assays that identify functional and structural cardiotoxicity earlier in the drug development pipeline has the potential to improve safety and the cost and time required to bring new drugs to market.
Presented by Jessica Palmer at the 11th World Congress on Alternatives and Animal Use in the Life Sciences; August, 2021
Assessing the accuracy, reproducibility, and applicability domain of new approach methods (NAMs) is necessary step for establishing confidence in these methods and enabling their use in a regulatory setting.
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Donna Troestlerhttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngDonna Troestler2021-08-30 12:47:022022-03-30 12:17:22Defining the Reproducibility and Applicability Domain of devTOX quickPredictTM, a Human Pluripotent Stem Cell-Based Developmental Toxicity Assay [WC11, 2021]
Presented by Jessica Palmer at the Society for Toxicology Meeting; March, 2021
Tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis for a wide range of cancers. Unfortunately, numerous TKIs produce cardiotoxic effects, which were not well predicted during preclinical studies.
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Donna Troestlerhttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngDonna Troestler2021-03-31 12:15:012022-03-30 12:17:44A Human Pluripotent Stem Cell-Based Assay, devTOX quickPredictTM, Accurately and Reproducibly Predicts the Developmental Toxicity Potential Across a Diverse Set of Chemicals [SOT, 2021]
Presented by Jessica Palmer at the American Society for Cellular and Computational Toxicology; October, 2020
Previous work showed that the potency ranking from devTOXqP assay was consistent with in vivo developmental toxicity potency, but whether the assay could quantitatively predict in vivo exposure exerting developmental toxicity was unknown.
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Donna Troestlerhttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngDonna Troestler2020-10-23 12:03:562022-03-30 12:18:35In Vitro to In Vivo Extrapolation for Developmental Toxicity Potency of Valproic Acid Analogues [ASCCT, 2020]
Presented by Jessica Palmer at the Safety Pharmacology Society Meeting in Barcelona, Spain; September, 2019
Tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis for a wide range of cancers. Unfortunately, numerous TKIs produce cardiotoxic effects, which were not well predicted during preclinical studies.
Presented at the Teratology Society Annual Meeting in San Diego, California; June 2019
Innovative in vitro toxicity screening assays aimed at reducing or replacing the use of animals in chemical safety testing are critical to meet the safety requirements across industries.
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Gina Wentlinghttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngGina Wentling2019-06-25 13:39:062022-03-30 12:21:57Developmental Toxicity Testing of Gaseous Chemicals with a Human Pluripotent Stem Cell-Based Assay [TSAM, 2019]
Presented by Imperial Brands at the British Toxicology Society Annual Congress, in Cambridge, UK; April 2019
There is a growing scientific consensus that next generation products (NGPs) present a less harmful alternative to cigarettes for adult smokers. However, further research is required to adequately assess if NGP aerosols present a developmental risk to the unborn foetus.
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Gina Wentlinghttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngGina Wentling2019-06-17 13:14:572022-03-30 12:22:39Next Generation Products Predicted to Have No Potential to Induce Developmental Toxicity in the devTOX quickPredictTM Assay [BTSAC, 2019]
Presented at FutureTox IV, a Society of Toxicology (SOT) Contemporary Concepts in Toxicology (CCT) meeting, in Arlington, VA; November 2018.
The ICH recently release the draft S5(R3) Guideline on Detection of Toxicity to Reproduction for Human Pharmaceuticals, which outlines the use of new approach methods (NAMs) in certain circumstances and provides a framework for qualifying a NAM for regulatory acceptance. Part of this framework is to assess the accuracy, demonstrate reproducibility, and define the applicability domain of a NAM…
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Gina Wentlinghttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngGina Wentling2018-11-16 15:10:162021-02-16 12:35:34Reproducibility and Applicability Domain of devTOX quickPredict, a Human Pluripotent Stem Cell-Based Developmental Toxicity Assay [FutureTox IV, 2018]
Presented at the Safety Pharmacology Annual Meeting in Washington, DC; September/October 2018
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% if safety-related withdrawals of FDA-approved drugs from the market. Current cardiac safety preclinical evaluations are heavily focused on electrophysiological assessment and fail to evaluate cardiomyopathy and other forms of structural cardiotoxicity…
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Gina Wentlinghttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngGina Wentling2018-10-08 15:07:152021-02-16 12:35:49Prediction of Cardiotoxicity Potential Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [SPS, 2018]
Presented at the American Society for Cellular and Computational Toxicology; September 2018
The reproductive and developmental toxicity requirements for registering chemical substances under REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) using whole-animal models could cost up to $8 billion and require the use of up to 22 million animals…
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Gina Wentlinghttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngGina Wentling2018-09-19 16:18:322021-02-16 12:36:19Human In Vitro Developmental Toxicity Assay Combined with a Read-Across Approach for Chemical Assessment [ASCCT, 2018]
Presented at the Teratology Society Annual Meeting in Clearwater, Florida; June 2018
Regulatory acceptance of alternative methods for toxicity testing remains a challenge despite international efforts to reduce animal use. Multiple agencies are working to develop a framework to implement the use of new approach methodologies for assessing the effects of chemical exposure on human health…
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Gina Wentlinghttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngGina Wentling2018-07-03 10:20:032021-02-16 12:24:50A Human Pluripotent Stem Cell-Based Assay Accurately Predicts the Developmental Toxicity Potency for a Series of Valproate Analogues [Teratology Society, 2018]
Presented at the Teratology Society Annual Meeting in Clearwater, Florida; June 2018.
This poster was presented by toxicology professionals from Syngenta, Ltd. The research they discussed was conducted using Stemina’s assays.
The current in vivo tests to identify chemistries with developmental and reproductive toxicity (DART) hazards are resource-intensive, relatively slow, and as such, are often undertaken too late in product development to inform subsequent chemical design, should an effect be seen.
Presented at the Society of Toxicology Annual Meeting and ToxEXPO in San Antonio, Texas, March 2018, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of the safety-related withdrawals of FDA-approved drugs from the market. Metabolic perturbations are one of the primary mechanisms of cardiotoxicity elicited by pharmaceuticals…
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Gina Wentlinghttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngGina Wentling2018-03-13 12:01:122019-03-06 11:38:22Development of an In Vitro Assay to Predict Cardiotoxicity Potential Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [SOT 2018]
Presented at the American College of Toxicology’s 38th Annual Meeting in Palm Springs, California in November 2017 by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of the safety related withdrawals of FDA-approved drugs from the market…
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Gina Wentlinghttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngGina Wentling2017-11-08 11:42:252019-03-08 11:32:03Development of a Targeted Biomarker Assay to Predict Cardiotoxicity Potential Using Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [ACT 2017]
Presented at the 10th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle, August 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
The development and use of alternative models of safety screening in place of animal models has been at the forefront of the toxicology field for over a decade; however, application of these assays in a regular setting is still poorly understood…
Presented at the Society of Toxicology’s Annual Meeting & ToxExpo in Baltimore, March 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Development and validation of in vitro models for developmental toxicity testing is essential for reducing the number of animals used toxicity testing. These assays have the potential to reduce or replace animal use in chemical safety testing for multiple industries, as well as to support ongoing worldwide…
https://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.png00Gina Wentlinghttps://stemina.com/wp-content/uploads/Stemina-Biomarker-Discovery-Logo-475x140.pngGina Wentling2017-03-14 13:22:012019-03-06 11:37:33Comparative Retrospective Analysis of In Vivo and In Vitro Developmental Toxicity Predictions [SOT 2017]
devTOX quickPredictTM Accurately Predicts the Developmental Toxicity Potential of the ICH S5(R3) Guideline Reference Compounds [BDRP, 2022]
/in Posters /by Donna TroestlerPresented by Jessica Palmer at the Society for Birth Defects and Research Meeting; June, 2022
There have been increased efforts in the pharmaceutical and chemical industries to incorporate new approach methods (NAMs) in vitro,, ex vivo, or in silico) earlier in the product development pipeline prior to in vivo testing.
devTOX quickPredictTM Accurately Predicts the Developmental Toxicity Potential of the ICH S5(R3) Guideline Reference Compounds [SOT, 2022]
/in Posters /by Donna TroestlerPresented by Jessica Palmer at the Society for Toxicology Meeting; March, 2022
There have been increased efforts in the pharmaceutical and chemical industries to incorporate new approach methods (NAMs) (in vitro, ex vivo, or in silico) earlier in the product development pipeline prior to in vivo testing.
A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential [WC11, 2021]
/in Posters /by Donna TroestlerPresented by Jessica Palmer at the 11th World Congress on Alternatives and Animal Use in the Life Sciences; August, 2021
Implementing screening assays that identify functional and structural cardiotoxicity earlier in the drug development pipeline has the potential to improve safety and the cost and time required to bring new drugs to market.
Defining the Reproducibility and Applicability Domain of devTOX quickPredictTM, a Human Pluripotent Stem Cell-Based Developmental Toxicity Assay [WC11, 2021]
/in Posters /by Donna TroestlerPresented by Jessica Palmer at the 11th World Congress on Alternatives and Animal Use in the Life Sciences; August, 2021
Assessing the accuracy, reproducibility, and applicability domain of new approach methods (NAMs) is necessary step for establishing confidence in these methods and enabling their use in a regulatory setting.
A Human Pluripotent Stem Cell-Based Assay, devTOX quickPredictTM, Accurately and Reproducibly Predicts the Developmental Toxicity Potential Across a Diverse Set of Chemicals [SOT, 2021]
/in Posters /by Donna TroestlerPresented by Jessica Palmer at the Society for Toxicology Meeting; March, 2021
Tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis for a wide range of cancers. Unfortunately, numerous TKIs produce cardiotoxic effects, which were not well predicted during preclinical studies.
In Vitro to In Vivo Extrapolation for Developmental Toxicity Potency of Valproic Acid Analogues [ASCCT, 2020]
/in Posters /by Donna TroestlerPresented by Jessica Palmer at the American Society for Cellular and Computational Toxicology; October, 2020
Previous work showed that the potency ranking from devTOXqP assay was consistent with in vivo developmental toxicity potency, but whether the assay could quantitatively predict in vivo exposure exerting developmental toxicity was unknown.
Biomarker-Based Prediction of Tyrosine Kinase Inhibitor Cardiotoxicity using Human iPSC-Derived Cardiomyocytes [SPSM, 2019]
/in Posters /by Donna TroestlerPresented by Jessica Palmer at the Safety Pharmacology Society Meeting in Barcelona, Spain; September, 2019
Tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis for a wide range of cancers. Unfortunately, numerous TKIs produce cardiotoxic effects, which were not well predicted during preclinical studies.
Developmental Toxicity Testing of Gaseous Chemicals with a Human Pluripotent Stem Cell-Based Assay [TSAM, 2019]
/in Posters /by Gina WentlingPresented at the Teratology Society Annual Meeting in San Diego, California; June 2019
Innovative in vitro toxicity screening assays aimed at reducing or replacing the use of animals in chemical safety testing are critical to meet the safety requirements across industries.
Next Generation Products Predicted to Have No Potential to Induce Developmental Toxicity in the devTOX quickPredictTM Assay [BTSAC, 2019]
/in Posters /by Gina WentlingPresented by Imperial Brands at the British Toxicology Society Annual Congress, in Cambridge, UK; April 2019
There is a growing scientific consensus that next generation products (NGPs) present a less harmful alternative to cigarettes for adult smokers. However, further research is required to adequately assess if NGP aerosols present a developmental risk to the unborn foetus.
Reproducibility and Applicability Domain of devTOX quickPredict, a Human Pluripotent Stem Cell-Based Developmental Toxicity Assay [FutureTox IV, 2018]
/in Posters /by Gina WentlingPresented at FutureTox IV, a Society of Toxicology (SOT) Contemporary Concepts in Toxicology (CCT) meeting, in Arlington, VA; November 2018.
The ICH recently release the draft S5(R3) Guideline on Detection of Toxicity to Reproduction for Human Pharmaceuticals, which outlines the use of new approach methods (NAMs) in certain circumstances and provides a framework for qualifying a NAM for regulatory acceptance. Part of this framework is to assess the accuracy, demonstrate reproducibility, and define the applicability domain of a NAM…
Prediction of Cardiotoxicity Potential Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [SPS, 2018]
/in Posters, Presentations /by Gina WentlingPresented at the Safety Pharmacology Annual Meeting in Washington, DC; September/October 2018
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% if safety-related withdrawals of FDA-approved drugs from the market. Current cardiac safety preclinical evaluations are heavily focused on electrophysiological assessment and fail to evaluate cardiomyopathy and other forms of structural cardiotoxicity…
Human In Vitro Developmental Toxicity Assay Combined with a Read-Across Approach for Chemical Assessment [ASCCT, 2018]
/in Posters /by Gina WentlingPresented at the American Society for Cellular and Computational Toxicology; September 2018
The reproductive and developmental toxicity requirements for registering chemical substances under REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) using whole-animal models could cost up to $8 billion and require the use of up to 22 million animals…
A Human Pluripotent Stem Cell-Based Assay Accurately Predicts the Developmental Toxicity Potency for a Series of Valproate Analogues [Teratology Society, 2018]
/in Posters /by Gina WentlingPresented at the Teratology Society Annual Meeting in Clearwater, Florida; June 2018
Regulatory acceptance of alternative methods for toxicity testing remains a challenge despite international efforts to reduce animal use. Multiple agencies are working to develop a framework to implement the use of new approach methodologies for assessing the effects of chemical exposure on human health…
Applying Discovery Toxicology Approaches for Prediction of Developmental Phenotypes [Teratology Society, 2018]
/in Posters /by Gina WentlingPresented at the Teratology Society Annual Meeting in Clearwater, Florida; June 2018.
This poster was presented by toxicology professionals from Syngenta, Ltd. The research they discussed was conducted using Stemina’s assays.
The current in vivo tests to identify chemistries with developmental and reproductive toxicity (DART) hazards are resource-intensive, relatively slow, and as such, are often undertaken too late in product development to inform subsequent chemical design, should an effect be seen.
Development of an In Vitro Assay to Predict Cardiotoxicity Potential Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [SOT 2018]
/in Posters /by Gina WentlingPresented at the Society of Toxicology Annual Meeting and ToxEXPO in San Antonio, Texas, March 2018, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of the safety-related withdrawals of FDA-approved drugs from the market. Metabolic perturbations are one of the primary mechanisms of cardiotoxicity elicited by pharmaceuticals…
Development of a Targeted Biomarker Assay to Predict Cardiotoxicity Potential Using Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [ACT 2017]
/in Posters /by Gina WentlingPresented at the American College of Toxicology’s 38th Annual Meeting in Palm Springs, California in November 2017 by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of the safety related withdrawals of FDA-approved drugs from the market…
EU-ToxRisk Case Study: Developmental Toxicity Potency of Valproate Analogues in Human Pluripotent Stem Cell-Based Assay [WC-10 (2017)]
/in Posters /by Gina WentlingPresented at the 10th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle, August 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
The development and use of alternative models of safety screening in place of animal models has been at the forefront of the toxicology field for over a decade; however, application of these assays in a regular setting is still poorly understood…
Comparative Retrospective Analysis of In Vivo and In Vitro Developmental Toxicity Predictions [SOT 2017]
/in Posters /by Gina WentlingPresented at the Society of Toxicology’s Annual Meeting & ToxExpo in Baltimore, March 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Development and validation of in vitro models for developmental toxicity testing is essential for reducing the number of animals used toxicity testing. These assays have the potential to reduce or replace animal use in chemical safety testing for multiple industries, as well as to support ongoing worldwide…